[1] WANG L, GAO P, ZHANG M, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J]. JAMA, 2017,317 (24):2515-2523. [2] ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016,375(9):905-906. [3] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏疾病防治临床指南[J].中华糖尿病杂志,2019,11(1):15-28. [4] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344. [5] CRUNKHORN S, PATTI M E. Links between thyroid hormone action, oxidative metabolism, and diabetes risk?[J]. Thyroid, 2008,18(2):227-237. [6] OHNO S,YOKOI H,MORI K,et al. Ablation of the N-type calcium channel ameliorates diabetic nephropathy with improved glycemic control and reduced blood pressure[J]. Sci Rep,2016,6:27192. [7] OZAIR M, NOOR S, RAQHAV A,et al. Prevalence of thyroid disorders in North Indian type 2 diabetic subjects: A cross sectional study[J]. Diabetes Metab Syndr, 2018,12(3):301-304. [8] SILVA RDO C. Importancia da avaliacao da funcao tireoidiana em pacientes com diabetes mellitus[J]. Arq Bras Endocrinol Metab, 2005, 49(2):180-182. [9] VIRGINI V S, WIJSMAN L W, RODONDI N, et al. Subclinical thyroid dysfunction and functional capacity among elderly[J]. Thyroid, 2014, 24(2):208-214. [10] CAI P, PENG Y, CHEN Y, et al. Blood pressure characteristics of subclinical hypothyroidism: an observation study combined with office blood pressure and 24-h ambulatory blood pressure[J]. J Hypertens, 2021,39(3):453-460. [11] DOSI R V, TANDON N. A study on prevalence of thyroid auto-immunity in type 1 diabetes mellitus[J]. J Indian Med Assoc, 2010,108(6):349-350, 355-356. [12] GONG Y,MA Y,YE Z, et al. Thyroid stimulating hormone exhibits the impact on LDLR/LDL-c via up-regulating hepatic PCSK9 expression[J]. Metabolism, 2017, 76: 32-41. [13] Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease[J]. Kidney Int, 2020,98(4S):S1-S115. |